Cancers · 2025
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bertuccio Francesco Rocco, Montini Simone, Fusco Maria Antonietta, Di Gennaro Antonella, Sciandrone Gaetano, Agustoni Francesco, Galli Giulia, Bortolotto Chandra, Saddi Jessica, Baietto Guido, Melloni Giulio, D'Ambrosio Gioacchino, Corsico Angelo Guido, Stella Giulia Maria
Аннотация
BACKGROUND: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6-18 months.
OBJECTIVES: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy.
METHODS: This review examines advancements in understanding PM's genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets.
RESULTS: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.
OBJECTIVES: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy.
METHODS: This review examines advancements in understanding PM's genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets.
RESULTS: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.